Kai Yang obtained his B.S. in Pharmacy at Nankai University in 2017. He achieved a M.S. in Medicinal Chemistry at Rutgers University in 2020. He focused on the design, synthesis, and biological evaluation of small-molecule uric acid and dihydroxyadenine inhibitors for the treatment of nephrolithiasis. Kai then joined Chempacific Corporation and developed and drafted clear synthetic strategies for complex molecules using state-of-the-art methodologies. He is eager to apply his knowledge in the basic and clinical sciences to discover and develop novel pharmaceuticals to treat and cure challenging human diseases.